

The primary headaches: genetics, epigenetics and a behavioural genetic model

Pasquale Montagna

Received: 14 January 2008 / Accepted: 4 February 2008 / Published online: 15 March 2008
© Springer-Verlag 2008

Abstract The primary headaches, migraine with (MA) and without aura (MO) and cluster headache, all carry a substantial genetic liability. Familial hemiplegic migraine (FHM), an autosomal dominant mendelian disorder classified as a subtype of MA, is due to mutations in genes encoding neural channel subunits. MA/MO are considered multifactorial genetic disorders, and FHM has been proposed as a model for migraine aetiology. However, a review of the genetic studies suggests that the FHM genes are not involved in the typical migraines and that FHM should be considered as a syndromic migraine rather than a subtype of MA. Adopting the concept of syndromic migraine could be useful in understanding migraine pathogenesis. We hypothesise that epigenetic mechanisms play an important role in headache pathogenesis. A behavioural model is proposed, whereby the primary headaches are construed as behaviours, not symptoms, evolutionarily conserved for their adaptive value and engendered out of a genetic repertoire by a network of pattern generators present in the brain and signalling homeostatic imbalance. This behavioural model could be incorporated into migraine genetic research.

Keywords Migraine · Tension-type headache · Cluster headache · Genetics · Epigenetics

Introduction

The genetics of the primary headaches scored recent scientific successes due to the unravelling of the genetics of

FHM. Deciphering of the patho-physiological mechanisms of these common diseases promises to bring the much needed knowledge for pharmacological treatments and therapeutic interventions. There are however also problems and controversies, some not solved by the genetic studies performed to date. The following is a brief subjective review of the available evidence, suggesting a role for epigenetic mechanisms and ending with the proposal of a behavioural model of the primary headaches possibly useful for the genetic studies.

Primary and secondary headaches: symptoms, syndromes or diseases? Idiopathic and syndromic migraines

Headaches/migraines are plagued by problems of definition: these terms describe *symptoms* (a feature which indicates a condition of disease, in particular one apparent to the patient, CED 2003), and at the same time, distinctive *syndromes* (a group of symptoms which consistently occur together) [1] or *diseases* (a disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms) [1] with recognisable diagnostic features, internationally defined [2]. The problems encountered with definitions become evident when dealing with primary or secondary headaches, and when considering idiopathic and syndromic migraines. Secondary headaches are those in which attacks occur due to a recognisable cause or disease, which itself represents the primary cause of the attacks. Syndromic migraines, contrasted with the idiopathic ones, are those in which attacks of migraine, clinically barely or not distinguishable from those occurring in the primary migraines, occur compounded with involvement of other systems. Syndromic migraines are

P. Montagna (✉)
Department of Neurological Sciences,
University of Bologna Medical School,
Via Ugo Foscolo, 7, 40123 Bologna, Italy
e-mail: pmontagn@kaiser.alma.unibo.it

often genetically determined. The concept of “syndromic,” potentially useful in the exploration of headache pathogenesis, has been applied to conditions such as deafness, visual loss and epilepsy, but has no place in the HCS classification that classifies headache attacks and not diseases, albeit distinguishing between primary and secondary headaches. These considerations may apply to the genetics of the primary headaches, since by adopting the HCS (2004), we consider symptoms, not diseases (much as if, studying the genetics of diabetes mellitus, we adopted a classification of the hyperglycemias).

Genetic epidemiology of the typical migraines

The typical primary migraines (MO and MA) all have a substantial risk of familial recurrence. When estimating the population relative risk of migraine in specified groups of relatives (i.e. the ratio between the probability that a relative versus a random member of the population is affected), first-degree relatives of migraine without aura probands have 1.9 times the risk of MO and 1.4 times the risk of MA, whereas first-degree relatives of MA probands have nearly four times the risk of MA and no increased risk of MO [3]. Since a family aggregation is implied when the risk ratio exceeds one, this confirms the familial liability for the migraines, even though familiarity is not yet heredity. A further analysis showed however that spouses of MO probands have 1.4 times the risk of MO, and spouses of MA probands have no increased risk of MA [3], thus backing a hereditary liability for MO and especially MA. Twin studies concur with this increased familial liability. Concordance rates for migraine are consistently higher among monozygotic (MZ) than dizygotic (DZ) twins. In particular, heritability estimates were around 52% in female twin pairs raised together or apart since infancy. In MZ Danish twin pairs, liability to MO resulted from additive genetic effects (61%) and from individual-specific environmental effects (39%), while in MA, correlation in liability was 0.68 in MZ and 0.22 in DZ, with heritability estimated at 0.65. Therefore, twin studies reveal that approximately one-half of the variation in migraine is attributable to additive genes, while the remainder is caused by unshared rather than shared environmental factors between twins [4, 5]. Several studies have analysed pedigrees with migraine, segregation analysis being performed to discover the genetic transmission pattern. Studies at first envisioned migraine as a simple mendelian disorder, inherited according to monogenic rules of transmission. Various modes of inheritance, autosomal dominant with female preponderance, possibly sex determined; autosomal recessive with 70% penetrance; polygenic; maternal and X-linked transmissions have been proposed, or rejected

[6, 7]. Finally, based on complex segregation analysis, a multifactorial inheritance was considered the most likely pattern even in high-risk families with MA [8]. A single gene was considered unlikely, but, notably, in some families, a mendelian or mitochondrial inheritance could not be excluded [3]. Currently, migraine is widely considered a complex disease with multifactorial inheritance. This type of inheritance applies to many complex/quantitative traits, i.e. traits that vary continuously in a phenotypic range, and in which variation is quantitative, not qualitative. Examples of quantitative traits are height, body weight, etc. Such traits are influenced by multiple genes (each a quantitative trait locus QTL), each having a small quantitative effect and interacting with the environment. However, there is still no unequivocal evidence that migraine as a quantitative trait varies continuously in the general population, and moreover, genetic variation underlying a continuous character distribution can result from segregation at a single locus too. Therefore, considering migraine as a quantitative trait may still be unwarranted.

The primary headaches also display considerable comorbidity, rarely incorporated into genetic studies. MA is comorbid with hypomania, depression and anxiety, and MO with phobia, panic and major depression. Other comorbidities are stroke, dyslipoproteinemias, essential tremor, paroxysmal dyskinesia and epilepsy. Merikangas et al. in a longitudinal genetic epidemiology study found that migraine was associated with mood disorders and drew attention to the fact that age at onset of anxiety disorders preceded, while onset of affective disorders followed that of migraine, findings consistent with a syndromic relationship between migraine and anxiety/depression [9].

These findings have been replicated, maternal depression being significantly associated with development of migraine in children [10]. Asthma, rhinitis and allergic bronchitis are also important comorbidities recurring in migraine families [11–13]. These comorbid clinical features should be properly incorporated in the genetic studies of the primary headaches.

Mendelian migraines? The genetics of FHM and their putative relationship with the typical migraines MA/MO

Migraines may be multifactorial, but mendelian migraines, i.e., migraines that conform to a mendelian type of genetic transmission, do exist. FHM is classified as a subtype of migraine with aura in the HCS (2004), and it conforms to an autosomal dominant pattern of hereditary transmission. Joutel et al. mapped FHM to chromosome 19, and in 1996 the first FHM gene, *CACNL1A4*, later termed *CACNA1A*, encoding the alpha1A subunit of the P/Q neural calcium

channel, was discovered, accounting for both FHM 1 and episodic ataxia type 2 (EA2) phenotypes [14, 15]. Spinocerebellar atrophy type 6 (SCA6) was added to the FHM and EA2 phenotypes in 1997 [16]. Thus, FHM 1, EA2 and SCA6 are all allelic channelopathies, with missense mutations mostly accounting for FHM, mutations disrupting the reading frame for EA2 and polyglutamine expansions in the COOH gene terminal for SCA6. The phenotypic spectrum of the *CACNA1A* mutations was at first believed to consist either of pure FHM or of FHM associated with cerebellar atrophy. Why some mutations originate pure FHM while others elicit progressive or intermittent cerebellar features remains unclear [17]. Ictal coma after trivial trauma and essential tremor were associated clinical features in families harbouring particular *CACNA1A* mutations. The phenotypic spectrum of the *CACNA1A* mutations has further expanded to include ataxia induced by fever or high temperature [18], childhood epilepsy [19,20] and status epilepticus [21], paroxysmal paranoid psychosis with anxiety [22], benign paroxysmal torticollis of infancy, considered a migraine equivalent [23], and even myasthenic syndrome [24], since *CACNA1A* is also expressed on presynaptic neuromuscular junction terminals where it modulates transmitter release [25] even in the absence of any morphological changes in the junction or muscle weakness [26].

The paroxysmal clinical features of migraine, ataxia and epilepsy, together with the consideration that *CACNA1A* specifies for a calcium channel and that in the tottering and leaner mouse with epilepsy and ataxia, similar mutations are found in the mouse homologue of the calcium channel $\alpha 1A$ subunit gene, led to the proposal that migraine be considered a calcium channelopathy [27]. The concept of migraine as a brain channelopathy fits well with the phenomenon of spreading depression [28], implicated in migraine attack pathophysiology. It is now accepted by the scientific community as an explicative model for migraine. However, the available genetic evidence is controversial or negative (see below).

FHM was soon proved to be genetically heterogeneous, some families linking to chromosome 1 [29,30], and a second gene, *ATP1A2*, encoding the $\alpha 2$ subunit of the Na/K ATPase, was discovered in Italian families and accounting for a phenotype of pure FHM (FHM 2) [31]. New mutations were found in FHM 2 pedigrees [32], and soon the phenotypic spectrum of FHM 2, initially thought to be confined to pure FHM, broadened to include such features as coma, triggered by minor head trauma and angiography [33], recurrent comas [34] and epilepsy, namely benign familial infantile febrile convulsions [35]. Finally, cerebellar ataxia associated with epilepsy and mental retardation was described in an Italian FHM 2

family [36,37], findings later confirmed by Spadaro et al. and Vanmolkot et al. in other families [38, 39]. Phenotypes of alternating hemiplegia of childhood [40–42] and basilar migraine [43] described with *ATP1A2* mutations further enlarged the clinical spectrum of FHM 2. Variability within the same family is notable, with FHM, cerebellar ataxia, recurrent paroxysmal dystonia and mental retardation all recurring together [42].

Lastly, mutations in the neuronal voltage-gated sodium channel *SCN1A* were reported by Dichgans et al. [44] to account for a phenotype of pure FHM (FHM 3), and there are still FHM families without mutations in any of the previously described genes, implying further genetic heterogeneity. Sporadic patients with HM, more common in clinical practice, also present problems, since mutations in the known FHM genes are only rarely encountered in this population [45].

An important corollary of the genetic discoveries obtained in the FHM was the proposal to consider FHM as a model for the typical migraines MO and MA [27]. This spurred the search for the involvement of FHM genes in MO/MA. Up to now the effort has been largely unrewarding. This in our opinion is also due to the misclassification of FHM as a subtype of MA [2], whereas FHM represents a syndromic migraine (see below). Some evidence in favour of linkage of typical migraines to the FHM locus on chromosome 19 was initially offered by May et al. [46], Nyholt et al. [47] and Terwindt et al. [48]. However, early negative studies [49–51] were later substantiated by systematic screening investigations of the *CACNA1A* in families with MO and/or MA [52–55], and to date, mutations in *CACNA1A* have never been demonstrated in kindreds without hemiplegic migraine, with or without aura. The same negative considerations apply to *ATP1A2*. Earlier evidence in favour of a role of the Chr1q31 locus or *ATP1A2* gene in the typical migraines [56, 57] was superseded by negative findings and absent *ATP1A2* mutations in typical migraine only pedigrees, even those displaying an apparently autosomal dominant mode of inheritance [58–61]. The FHM 3 *SCN1A* gene was discovered too recently for any conclusive study. Von Brevern et al. [62] however failed to find any *CACNA1A*, *ATP1A2* or *SCN1A* mutations in patients with migrainous vertigo. Thus, there is no current evidence that the genes causing FHM represent major susceptibility loci for the typical migraines.

Does such negative genetic evidence imply that FHM is not a useful model for migraine etiology? Several reviews of migraine pathogenesis apply the FHM model of neural channelopathy to the typical migraines. While such models are not justified genetically, it may be contended that FHM is nonetheless helpful in elucidating the pathophysiology of

Table 1 A list of proposed (and provisional) syndromic migraines

Syndromic migraines	Genes (chromosome) involved	Migrainous features (references)
MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes)	<i>MTTL1</i> , <i>MTTQ</i> , <i>MTHH</i> , <i>MTTK</i> , <i>MTTS1</i> , <i>MTND1</i> , <i>MTND5</i> , <i>MTND6</i> , and <i>MTTS2</i> (mtDNA)	Most frequent symptom: episodic sudden headache with vomiting and convulsions [63, 64]
CADASIL (cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy)	<i>NOTCH 3</i> (19p13.2–p13.1)	MA in 22% [65]; migraine in 38% [66]
HERNS (retinopathy, vascular, with cerebral and renal involvement and Raynaud and migraine phenomena)	<i>TREX1</i> (3p21.3–p21.2)	Migraine in 70% [67]
CCM (familial cerebral cavernous malformations)	<i>KRYT 1</i> (7q11.2–q21)	Convulsions and migraine attacks [68, 69]

the migraine attacks. This consideration however is likely to apply to several clinical conditions all characterised by headache attacks of the migraine type. Migraine-like attacks indeed are found not only in the typical migraines, but also in other conditions, diseases or syndromes, in which they occur together with symptoms and signs of multisystem nervous or extra-nervous involvement. These “syndromic migraines” thus display bona fide migraine headache attacks at some times in their clinical course, and most of them have a genetic basis (Table 1). FHM is also characterised by multisystem neurologic involvement (migraine, hemiplegia, ictal recurrent comas, cerebellar atrophy, mental retardation, epilepsy, movement disorders, myasthenic syndrome, etc.), and therefore we make a plea for FHM to be considered more appropriately as a syndromic migraine and not a subtype of MA, as with the current HCS classification (2004).

Linkage and association studies in the typical migraines

Several studies on the genetics of the typical migraines MO and MA applied genetic association, linkage and genome wide scanning methods. Most of these studies resulted in findings that either lack verification or are controversial. For MA, a genome wide scan on 50 multigenerational families in Finland identified a susceptibility locus on chromosome 4q24 [70]. Other loci for MA have been reported on chromosome 11q24 in Canadian families with an autosomal dominant transmission pattern [71], and on chromosome 15q11–q13 to a genomic region containing genes encoding for GABA-A receptors in ten Italian families again displaying an autosomal dominant transmission pattern [72].

For MO, or for pedigrees with MO mixed with MA, susceptibility loci have been reported on chromosome 6p12.2–p21.1 in Sweden [73], chromosome 5q21 [74], chromosome 14q21.2–q22.3 in an Italian family with MO [75], chromosome Xq24–28 in two large Australian

pedigrees [76] and chromosome 19p13.3/2 to the insulin receptor gene *INSR* [77]. While many of such findings have still to be replicated, in some cases (the *INSR* gene) sequence studies have given negative results [78].

Other studies have examined candidate genes, implying that a pathogenetic (and a priori) hypothesis was formulated beforehand. This may be risky, considering that the pathogenesis of the migraine headaches is still imperfectly understood. Candidate genes explored were the mitochondrial DNA (mtDNA), or genes involved in prothrombotic or cardiovascular disease, or in the metabolism of biologic amines such as dopamine or serotonin, or in a variety of other metabolic systems. Several of the studies applied to mtDNA genes have yielded negative results, even though in some families migraine was reported to segregate with the Leber mtDNA 14484 mutation [79], and mtDNA mutations and haplotypes (haplotype U) have been associated with juvenile migraine stroke [80, 81] and with cyclic vomiting, considered a migraine equivalent in the pediatric population [82–84]. Contrasting results for genes involved in prothrombotic/cardiovascular risk, and for those involved in the metabolism of the biological amines serotonin and dopamine, or in several other metabolic pathways are summarised in Tables 2, 3, 4, and 5.

Finally, a few studies have focused on the genetics of the chronic headaches, a major social problem, since these chronic headaches are often associated with drug abuse and afflict a remarkable percentage of the general population. Chronic tension-type headache displays a substantial familial recurrence, with lifetime relative risk estimated at 3.87 for parents and 3.53 for children of probands; the risk is greater for females (3.35) than for males (2.59) [85]. A genetic association study of chronic headache with drug abuse versus the dopamine metabolism genes by Cevoli et al. [86] found that allele 4 of the exon III VNTR polymorphism of the dopamine receptor 4 gene *DRD4* was associated with chronic daily headache, and allele 9 of the dopamine transporter gene *SLC6A3* was more common in

Table 2 Prothrombotic and cardiovascular risk genes and typical migraine genetics

Prothrombotic/vascular risk genes or mutations examined	Phenotypes
LDL receptor (19p13.2)	Associated with MO [87]; not associated [88]
Factor V R/Q 506 (Leiden mutation)	Associated with MA [89] Not associated with migraine stroke [90]; not associated with MA/MO [91]; not associated with juvenile MA [92]
Factor II 20210 G/A	Not associated with MA/MO [91] Not associated with migraine stroke [93]
Factor XIII Val 34 <i>Leu</i>	Not associated with migraine [94]
Decanucleotide insertion/deletion factor VII promoter	Not associated with MA/MO [91]
Alloantigenic platelet systems HPA-1 and HPA-2	Not associated with MA/MO [91]
Deficit of protein S	Associated with MA [89]
Angiotensin converting enzyme (<i>ACE</i>)	Allele D associated with MO and more frequent migraine attacks [95]
Endothelial NO synthase inducible (<i>NOS3</i> ; <i>iNOS</i>)	Not associated with migraine [96, 97]
Endothelin receptor A (<i>ETA-231 A/G</i>) polymorphism	Allele G protecting from migraine [98]
<i>MTHFR</i> (methylene-tetra-hydrofolate reductase) C677T/A1298C	Homozygous mutation associated with MA [99], associated with MA [100]; risk for MA, modulated by thymidilate synthase gene [101]

Table 3 Serotonin metabolism genes and typical migraine genetics

Serotonin metabolism genes examined	Phenotypes
<i>5-HTSERT</i> (17q11.2–12)	Allelic association with MO (increase of allele STin2.12 + decrease of allele STin2.10) and MA (same + increase of allele Stin2.9) [102]; 5HT-TLPR with MA [103] Allelic association with migraine (allele Stin2.10) [104]; borderline association with migraine [105] No association/linkage with migraine [106, 107]
<i>5-HT2A</i> (13q14–21)	Allelic (allele C) association with migraine aura [108] No association with migraine [105, 106, 109, 110]
<i>5-HT1B</i> (6q13)	No association with migraine [106, 110, 111]
<i>5-HT1D</i> (1p36.3–34.3)	No association with migraine [106, 110, 111]
<i>5-HT2B</i> (2q36.3–q37.1)	No association with migraine [106, 110, 111]
<i>5-HT2C</i> (Xq22–25)	No association with migraine [106, 110, 111]
<i>5-HT1B</i> (6q13)	No association with therapeutic response to triptans [112, 113]
<i>5-HT1F</i> (3p12)	No association with therapeutic response to triptans [112, 113]

chronic daily headache associated with drug abuse than in episodic migraine.

Genetics of tension-type headache

Remarkably, apart from an epidemiological genetic study that demonstrated a familial aggregation for chronic tension-type headache [85], there are no other genetic studies of this common disorder.

Genetics of cluster headache

Cluster headache (CH) has long been considered a sporadic disease. In recent decades, however, a familial recurrence has been appreciated, and the new HCS classification (2004) now states that CH may be transmitted as an autosomal dominant disease in about 5% of cases. Several CH cases have been reported among monozygotic twins and in family pedigrees [129–137], and family studies indicate that I-degree relatives of CH probands carry a 5- to 18-fold, and

Table 4 Dopamine metabolism genes and typical migraine genetics

Genes examined	Phenotypes
Dopamine receptor 2 (<i>DRD2</i>)	Allelic association (allele NcoI) with MA comorbid with anxiety/depression [114] Allelic association (allele 1) with yawning/nausea during attack of MO [115] No allelic association (allele NcoI) with MA [116] No allelic association with MO/MA [107, 117, 118, 119]
Dopamine receptors 1, 3, 4, 5 (<i>DRD1, DRD3, DRD4, DRD5</i>)	No allelic association with migraine [115, 117, 120]
Dopamine transporter (<i>DAT</i>)	Association with chronic daily headache with drug abuse [86]
<i>COMT; MAO-A</i>	No association with migraine [117, 121]
Dopamine-beta-hydroxylase (<i>DBH</i>)	Association with migraine [107], especially males with MA [122] No association [123]

Table 5 Other genes implicated in typical migraine genetics

Genes examined	Phenotypes
Androgen/progesterone receptors	Androgen receptor not associated; progesterone receptor associated with migraine [124]
K channel <i>KCNN3</i>	Allelic association (CAG repeats) with MO/MA [125] Not associated (CAG repeats) [126]
Cytotoxic T lymphocyte antigen 4 (<i>CTLA-4</i>)	Not associated with migraine [127]
<i>HLA-DRB1</i>	Allelic association with MA [128]

II-degree relatives a 1- to 3-fold increased relative risk of the disease [138–141]. CH has been considered a probable autosomal dominant disease with a penetrance of 0.3–0.34 in males and 0.17–0.21 in females [142]. The exact transmission pattern is however still debated [143, 144], and an autosomal recessive pattern has been advocated in certain families [137]. Several candidate genes have been analysed, in particular mtDNA mutations [145–148], HLA antigens [149–151] and *CACNA1A* polymorphisms [152, 153], usually with negative or controversial results. Other genes, such as the NO synthases *NOS1*, *NOS2A* and *NOS3* [154], the elusive amine gene cluster [155], the *CLOCK* gene involved in the regulation of circadian rhythms [156, 157] and the hemochromatosis gene [158], have been found not associated with CH. Recently, an association between CH and a polymorphism in the hypocretin receptor 2 gene *HCRTR2* was reported by Rainero et al. [159], possibly accounting for the circadian recurrence of the CH attacks. Such an association, while confirmed by Schürks et al. [160], was rejected in a European multicentric study [161]. Recently, reports of CH associated with hemiparesis during the attacks suggested a relationship with FHM and ionic channelopathies [162]. Preliminary genic expression studies instead documented the activation of proinflammatory genes during the CH attack [163].

Genetics and epigenetics

Epigenetics is the study of the changes in DNA and DNA-binding proteins that, albeit altering the structure of chromatin, do not modify the nucleotide sequence of DNA. The remarkable feature here is that some of these modifications may be associated with heritable changes in gene function.

Commonly held concepts of heredity indeed pit environmental influences (nurture) against genetic background (nature) as totally separate causative factors. Genetic advances themselves have however demonstrated that the hereditary transmission of biological changes not encoded in the DNA sequence and dictated by environmental influences is possible. This part of genetics, called epigenetics, has received little or no attention in the genetic studies of the primary headaches. It is the contention of the author however that future epigenetic studies will account for several hereditary features of the primary headaches, in particular their comorbidities.

All those (meiotic and mitotic) modifications in gene expression that are heritable but not encoded in the DNA sequence are defined as epigenetic. Molecular mechanisms implicated include (1) methylation of cytosine residues at C5 in dinucleotide CpG sites (localised especially in promoters of well over 40% of the genes and that, when

methylated, cause silencing of the gene); (2) mechanisms of RNA interference, whereby microRNAs silence gene expression; (3) histone (DNA associated proteins) changes: activation or inactivation of genomic regions according to the “histone code”. All of these mechanisms result in the expression or silencing of genes, and underlie such phenomena as inactivation of the X chromosome and genomic imprinting. Several epigenetic diseases are already known that may be inherited through the somatic and the germinal line: fragile X syndrome, in which *ATRX* gene mutations modify the methylation pattern of ribosomal RNA and, by methylation of CGG expansions in the *FMR1* gene, silence the gene; the Angelman and Prader-Willi, and Rett syndromes; also, many colonic cancers and leukemias. Important epigenetic differences that increase with age are found even between monozygotic twins [164]. Notably, epigenetic modifications may increase with age and may also be prevented through interventions directed at DNA or histone methylation (with azanucleotides, antisense oligonucleotides, histone deacetylase). Even more remarkably, there is some evidence that lifestyles and even diet may play a role [165].

Epigenetic models for the primary headaches?

There is consistent evidence that behavioural differences typical of specific inbred animal strains are the consequence of environmental influences acting especially during development rather than DNA changes. Mice strains with decreased environmental exploration behaviour (B6 strain) develop enhanced exploratory behaviour if nurtured in their first 3 months of life by BALB dams, a strain displaying intense exploratory behaviour; changes in behaviour appear to be linked to the type of maternal care, particularly licking of the pup by the mother, a behaviour demonstrated to affect the status of the endocrine stress system in mice [166]. Weaver et al. [167] showed how maternal care in the rat (licking and grooming the pup) modifies the methylation pattern of the promoter of the glucocorticoid receptor gene in the hippocampus; such epigenetic changes, evident from the first week of life, persist throughout the animal’s life but are reversible upon treatment with histone deacetylase inhibitors or upon intracerebral administration of methionine (an intervention that modifies the methylation pattern) [168].

Stress plays a remarkable role in the development of the nervous system: removal of rat pups from the mother causes reduced neurogenesis in the adult hippocampus through steroid-dependent mechanisms [169], and alters serotonergic transporter densities and serotonergic 1A receptors in the rat brain [170]. Administration of steroids to the mother before delivery causes changes in behavioural patterns in

juvenile rats [171], and maternal deprivation in the immediate post-natal period modifies locomotor and steroid release patterns in the adult rat [172]. Epigenetic mechanisms also seem relevant for the formation of memory traces [173] and more generally for cognitive development [174]. Epigenetic mechanisms have been hypothesised for psychiatric disorders [175, 176] and many complex and multifactorial diseases affecting the brain or the inflammatory and immune systems [177–179].

There are still no studies of epigenetic mechanisms in the primary headaches. When considering, however, the important maternal influence in migraine genetics; the consistent and inherited co-morbidities especially for psychiatric and inflammatory-immune disorders; twin studies documenting that only about half of the variability is due to “genetic” factors; it is possible to envision that epigenetic mechanisms, especially those acting during nervous system development in early infancy and childhood, play a role in the heritability and pathophysiology of the primary headaches. Preliminary studies have already analysed attachment styles in adult migraineurs [180, 181], and a prospective investigation demonstrated correlations between events suffered during pregnancy and early life, and quality of adult life 31–33 years later [182]. It is reasonable to suggest that early life factors and attachment styles between mother and child represent determinants of epigenetic changes relevant in migraine pathogenesis. Such early pre- and post-natal environmental behavioural factors could be usefully analysed to define endophenotypes of adaptive behaviour useful in the genetic studies of the primary headaches.

Final comments: a behavioural model of the primary headaches as fight-or-flight response and sickness behaviour to be incorporated into genetic research

Consideration of epigenetic mechanisms may help in analysing behaviours during the headache attacks. Any genetic studies are ultimately dependent upon the definition of the phenomenon taken into consideration, and on how it is conceptualised. Therefore, studies have to rely upon conventional diagnostic criteria, in turn based on a priori interpretations. Most genetic studies have been performed within the frame of migraine interpreted simply as a “pain” trait with multifactorial inheritance. In a “harlequin” model, several genetic factors, each one having a small specific weight, interact with environmental factors to determine the migraine attack. Such a model should however be better tailored to suit phenomena such as the migraine attack and the migraine diseases that are really behavioural “processes” with an intrinsic logic of their own [183], one that is consistent within attacks, within

patients and within populations. There is a need to conceive of the primary headaches along more useful scientific lines. Consistently lacking in the genetic studies is for instance any consideration of migraine as a behavioural response to environmental and/or endogenous triggers, a view that has scientific support [184] and that we recently revised to accommodate a Darwinian perspective [185]. According to our view, migraine and other primary headaches such as CH are behaviours, not symptoms, evolutionarily conserved for their adaptive value and engendered out of a genetic repertoire by networks of pattern generators present in the brain. These neural networks serve the homeostasis of the brain, with migraine pain considered a kind of visceral pain signalling homeostatic imbalance. The behavioural repertoire enacted during the migraine attack, complete with its full panoply of pain, cognitive, autonomic, motor, etc., symptoms and signs, is comparable to that defined as *sickness behaviour* and already known to develop in all mammals and other animals following challenge with infective and other pathogenic agents [186]. In contrast, behaviour during the CH attacks [187] resembles the *fight-or-flight response* of hypothalamic animals. These behaviours during the headache attacks really represent “healing” processes, and migraine may even be evolutionarily advantageous [188]. Thus, what is relevant in this new behavioural model is not the manifestations of the attack, but the factors triggering it, that, migraine being of the brain, must relate to still unknown disturbances of brain homeostasis [185]. Accordingly, it is these triggering factors rather than the manifestations during the attacks that may represent the features most relevant for a true dissection of the genetics of the primary headaches.

Acknowledgments I wish to thank Ms. A. Laffi for help with the manuscript, and A. Collins for revising the English text. Supported by MIUR grants. This review results from the lesson of the Author at the Master in Headache Medicine, Sapienza University of Rome, during the Academic Year 2007–2008.

References

1. The Compact English Dictionary, 11th edn. Oxford University Press, Oxford, pp 1–1378
2. Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders. *Cephalalgia* 24:1–160
3. Russell MB, Iselius L, Olesen J (1996) Migraine without aura and migraine with aura are inherited disorders. *Cephalalgia* 16:305–309
4. Ulrich V, Gervil M, Kyvik KO, Olesen J, Russell MB (1999) The inheritance of migraine with aura estimated by means of structural equation modelling. *J Med Genet* 36:225–227
5. Russell MB, Ulrich V, Gervil M, Olesen J (2002) Migraine without aura and migraine with aura are distinct disorders. A population-based twin survey. *Headache* 42:332–336
6. Devoto M, Lozito A, Staffa G, D’Alessandro R, Sacquegna T, Romeo G (1986) Segregation analysis of migraine in 128 families. *Cephalalgia* 6:101–105
7. Mochi M, Sangiorgi S, Cortelli P, Carelli V, Scapoli C, Crisci M, Monari L, Pierangeli G, Montagna P (1993) Testing models for genetic determination in migraine. *Cephalalgia* 13:389–394
8. Ulrich V, Russell MB, Ostergaard S, Olesen J (1997) Analysis of 31 families with an apparently autosomal-dominant transmission of migraine with aura in the nuclear family. *Am J Med Genet* 74:395–397
9. Merikangas KR, Merikangas JR, Angst J (1993) Headache syndromes and psychiatric disorders: association and familial transmission. *J Psychiatr Res* 27:197–210
10. Mortimer MJ, Kay J, Jaron A, Good PA (1992) Does a history of maternal migraine or depression predispose children to headache and stomach-ache? *Headache* 32:353–355
11. Chen TC, Leviton A (1990) Asthma and eczema in children born to women with migraine. *Arch Neurol* 47:1227–1230
12. Mortimer MJ, Kay J, Gawkrödger DJ, Jaron A, Barker DC (1993) The prevalence of headache and migraine in atopic children: an epidemiological study in general practice. *Headache* 33:427–431
13. Gurkan F, Ece A, Haspolat K, Dikici B (2000) Parental history of migraine and bronchial asthma in children. *Allergol Immunopathol (Madr)* 28:15–17
14. Joutel A, Bousser MG, Bioussé V, Labauge P, Chabriat H, Nibbio A, Maciazek J, Meyer B, Bach MA, Weissenbach J et al (1993) A gene for familial hemiplegic migraine maps to chromosome 19. *Nat Genet* 5:40–45
15. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mührenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca²⁺ channel gene CACNL1A4. *Cell* 87:543–552
16. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. *Nat Genet* 15:62–69
17. Alonso I, Barros J, Tuna A, Seixas A, Coutinho P, Sequeiros J, Silveira I (2004) A novel R1347Q mutation in the predicted voltage sensor segment of the P/Q-type calcium-channel alpha-subunit in a family with progressive cerebellar ataxia and hemiplegic migraine. *Clin Genet* 65:70–72
18. Subramony SH, Schott K, Raike RS, Callahan J, Langford LR, Christova PS, Anderson JH, Gomez CM (2003) Novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits. *Ann Neurol* 54:725–731
19. Jouvenceau A, Eunson LH, Spauschus A, Ramesh V, Zuberi SM, Kullmann DM, Hanna MG (2001) Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. *Lancet* 358:801–807
20. Kors EE, Melberg A, Vanmolkot KR, Kumlien E, Haan J, Raininko R, Flink R, Ginjaar HB, Frants RR, Ferrari MD, van den Maagdenberg AM (2004) Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new CACNA1A mutation. *Neurology* 63:1136–1137
21. Beauvais K, Cave-Riant F, De Barace C, Tardieu M, Tournier-Lasserre E, Furby A (2004) New CACNA1A gene mutation in a case of familial hemiplegic migraine with status epilepticus. *Eur Neurol* 52:58–61
22. Spranger M, Spranger S, Schwab S, Benninger C, Dichgans M (1999) Familial hemiplegic migraine with cerebellar ataxia and paroxysmal psychosis. *Eur Neurol* 41:150–152

23. Giffin NJ, Benton S, Goadsby PJ (2002) Benign paroxysmal torticollis of infancy: four new cases and linkage to CACNA1A mutation. *Dev Med Child Neurol* 44:490–493
24. Maselli RA, Kong DZ, Bowe CM, McDonald CM, Ellis WG, Agius MA, Gomez CM, Richman DP, Wollmann RL (2000) Presynaptic congenital myasthenic syndrome due to quantal release deficiency. *Neurology* 57:279–289
25. Plomp JJ, Vergouwe MN, van den Maagdenberg AM, Ferrari MD, Frants RR, Molenaar PC (2000) Abnormal transmitter release at neuromuscular junctions of mice carrying the tottering alpha(1A) Ca(2+) channel mutation. *Brain* 123(Pt 3):463–471
26. Kaja S, van de Ven RC, Broos LA, Veldman H, van Dijk JG, Verschuuren JJ, Frants RR, Ferrari MD, van den Maagdenberg AM, Plomp JJ (2005) Gene dosage-dependent transmitter release changes at neuromuscular synapses of CACNA1A R192Q knockin mice are non-progressive and do not lead to morphological changes or muscle weakness. *Neuroscience* 135:81–95
27. Terwindt GM, Ophoff RA, Haan J, Sandkuijl LA, Frants RR, Ferrari MD (1998) Migraine, ataxia and epilepsy: a challenging spectrum of genetically determined calcium channelopathies. Dutch Migraine Genetics Research Group. *Eur J Hum Genet* 6:297–307
28. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LAM, Cesetti T, van de Ven RCG, Tottene A, van der Kaa J, Plomp JJ, Frants RR, Ferrari MD (2004) A CACNA1A knockin migraine mouse model with increased susceptibility to cortical spreading depression. *Neuron* 41:701–710
29. Gardner K, Barmada MM, Ptacek LJ, Hoffman EP (1997) A new locus for hemiplegic migraine maps to chromosome 1q31. *Neurology* 49:1231–1238
30. Ducros A, Joutel A, Vahedi K, Cecillon M, Ferreira A, Bernard E, Verier A, Echenne B, Lopez de Munain A, Boussier MG, Tournier-Lasserre E (1997) Mapping of a second locus for familial hemiplegic migraine to 1q21–q23 and evidence of further heterogeneity. *Ann Neurol* 42:885–890
31. De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, Ballabio A, Aridon P, Casari G (2003) Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha 2 subunit associated with familial hemiplegic migraine type 2. *Nat Genet* 33:192–196
32. Riant F, De Fusco M, Aridon P, Ducros A, Ploton C, Marchelli F, Maciazek J, Boussier MG, Casari G, Tournier-Lasserre E (2005) ATP1A2 mutations in 11 families with familial hemiplegic migraine. *Hum Mutat* 26:281
33. Pierelli F et al (2006) A novel ATP1A2 mutation in a family with FHM type II. *Cephalalgia* 26:324–328
34. Echenne B, Ducros A, Rivier F, Joutel A, Humbertclaude V, Roubertie A, Azais M, Boussier MG, Tournier-Lasserre E (1999) Recurrent episodes of coma: an unusual phenotype of familial hemiplegic migraine with linkage to chromosome 1. *Neuropediatrics* 30:214–217
35. Vanmolkot KR, Kors EE, Hottenga JJ, Terwindt GM, Haan J, Hoefnagels WA, Black DF, Sandkuijl LA, Frants RR, Ferrari MD, van den Maagdenberg AM (2003) Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. *Ann Neurol* 54:360–366
36. Cevoli S, Pierangeli G, Monari L, Valentino ML, Bernardoni P, Mochi M, Cortelli P, Montagna P (2002) Familial hemiplegic migraine: clinical features and probable linkage to chromosome 1 in an Italian family. *Neurol Sci* 23:7–10
37. Jurkat-Rott K, Freilinger T, Dreier JP, Herzog J, Gobel H, Petzold GC, Montagna P, Gasser T, Lehmann-Horn F, Dichgans M (2004) Variability of familial hemiplegic migraine with novel ATP1A2 Na+/K+-ATPase variants. *Neurology* 62:1857–1861
38. Spadaro M, Ursu S, Lehmann-Horn F, Liana V, Antonini G, Giunti P, Frontali M, Jurkat-Rott K (2004) A G301R Na+/K+-ATPase mutation causes familial hemiplegic migraine type 2 with cerebellar signs. *Neurogenetics* 5:177–185
39. Vanmolkot KR, Stroink H, Koenderink JB, Kors EE, van den Heuvel JJ, van den Boogerd EH, Stam AH, Haan J, De Vries BB, Terwindt GM, Frants RR, Ferrari MD, van den Maagdenberg AM (2006) Severe episodic neurological deficits and permanent mental retardation in a child with a novel FHM2 ATP1A2 mutation. *Ann Neurol* 59:310–314
40. Bassi MT, Bresolin N, Tonelli A, Nazos K, Crippa F, Baschir-otto C, Zucca C, Bersano A, Dolcetta D, Boneschi FM, Barone V, Casari G (2004) A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood. *J Med Genet* 41:621–628
41. Auvin S, Joriot-Chekaf S, Cuvelier JC, Vallee L (2004) Familial alternating hemiplegia of childhood or channelopathy? A report with valuable pathophysiological implications. *Dev Med Child Neurol* 46:500
42. Swoboda KJ, Kanavakis E, Xaidara A, Johnson JE, Leppert MF, Schlesinger-Massart MB, Ptacek LJ, Silver K, Youroukos S (2004) Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation. *Ann Neurol* 55:884–887
43. Ambrosini A, D'Onofrio M, Grieco GS, Di Mambro A, Montagna G, Fortini D, Nicoletti F, Nappi G, Sances G, Schoenen J, Buzzi MG, Santorelli FM, Pierelli F (2005) Familial basilar migraine associated with a new mutation in the ATP1A2 gene. *Neurology* 65:1826–1828
44. Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz B, Biskup S, Ferrari MD, Herzog J, van den Maagdenberg AM, Pusch M, Strom TM (2005) Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. *Lancet* 366:371–377
45. Terwindt G et al (2002) Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. *Arch Neurol* 59:1016–1018
46. May A, et al (1995) Familial hemiplegic migraine locus on 19p13 is involved in the common forms of migraine with and without aura. *Hum Genet* 96:604–608
47. Nyholt DR et al (1998) Familial typical migraine: linkage to chromosome 19p13 and evidence for genetic heterogeneity. *Neurology* 50:1428–1432
48. Terwindt GM et al (2001) Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. *Neurology* 56:1028–1032
49. Hovatta I et al (1994) Familial migraine: exclusion of the susceptibility gene from the reported locus of familial hemiplegic migraine on 19p. *Genomics* 23:707–709
50. Monari L et al (1997) Searching for migraine genes: exclusion of 290 cM out of the whole human genome. *Ital J Neurol Sci* 18:277–282
51. Kim JS et al (1998) Familial migraine with vertigo: no mutations found in CACNA1A. *Am J Med Genet* 79:148–151
52. Brugnoli R et al (2002) Is the CACNA1A gene involved in familial migraine with aura? *Neurol Sci* 23:1–5
53. Noble-Topham S et al (2001) Migraine with aura is not linked to the FHM gene CACNA1A or the chromosomal region, 19p13. *Genomics* 78:150–154
54. Jones KW et al (2002) Migraine with aura susceptibility locus on chromosome 19p13 is distinct from the familial hemiplegic migraine locus. *Neurology* 59:1099–1101
55. Wieser T et al (2003) Absence of known familial hemiplegic migraine (FHM) mutations in the CACNA1A gene in patients with common migraine: implications for genetic testing. *Clin Chem Lab Med* 41:272–275

56. Todt U et al (2005) Rare missense variants in ATP1A2 in families with clustering of common forms of migraine. *Hum Mutat* 26:315–321
57. Lea RA et al (2002) A typical migraine susceptibility region localizes to chromosome 1q31. *Neurogenetics* 4:17–22
58. Curtain RP et al (2005) Analysis of chromosome 1 microsatellite markers and the FHM2-ATP1A2 gene mutations in migraine pedigrees. *Neurol Res* 27:647–652
59. Jen JC, Kim GW, Dudding KA, Baloh RW (2004) No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. *Arch Neurol* 61:926–928
60. Kirchmann M et al (2006) The CACNA1A and ATP1A2 genes are not involved in dominantly inherited migraine with aura. *Am J Med Genet B Neuropsychiatr Gen* 141:250–256
61. Netzer C et al (2006) Haplotype-based systematic association studies of ATP1A2 in migraine with aura. *Am J Med Genet* 141:257–260
62. von Brevern M et al (2006) Migrainous vertigo: mutation analysis of the candidate genes CACNA1A, ATP1A2, SCN1A, and CACNB4. *Headache* 46:1136–1141
63. Goto Y, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M, Nonaka I (1992) Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. *Neurology* 42:545–550
64. Montagna P, Gallassi R, Medori R, Govoni E, Zeviani M, Di Mauro S, Liguori E, Andermann F (1988) MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. *Neurology* 38:751–754
65. Chabriat H, Vahedi K, Iba-Zizen MT, Joutel A, Nibbio A, Nagy TG, Krebs MO, Julien J, Dubois B, Ducrocq X, Levasseur M, Homeyer P, Mas JL, Lyon-Caen O, Tournier Lasserre E, Bousser MG (1995) Clinical spectrum of CADASIL: a study of 7 families. *Lancet* 346:934–939
66. Dichgans M, Mayer M, Uttner I, Bruning R, Muller-Hocker J, Rungger G, Ebke M, Klockgether T, Gasser T (1998) The phenotypic spectrum of CADASIL: clinical findings in 102 cases. *Ann Neurol* 44:731–739
67. Ophoff RA, DeYoung J, Service SK, Joosse M, Caffo NA, Sandkuijl LA, Terwindt GM, Haan J, van den Maagdenberg AMJM, Jen J, Baloh RW, Barilla-LaBarca M-L, Saccone NL, Atkinson JP, Ferrari MD, Freimer NB, Frants RR (2001) Hereditary vascular retinopathy, cerebrotretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1–p21.3. *Am J Hum Genet* 69:447–453
68. Michael JC, Levin PM (1936) Multiple telangiectases of brain: a discussion of hereditary factors in their development. *Arch Neurol Psychiatry* 36:514–536
69. Marini V, Ferrera L, Dorcaratto A, Viale G, Origone P, Mareni C, Garrè C (2003) Identification of a novel KRIT1 mutation in an Italian family with cerebral cavernous malformation by the protein truncation test. *J Neurol Sci* 212:75–78
70. Wessman M, Kallela M, Kaunisto MA, Marttila P, Sobel E, Hartiala J, Oswell G, Leal SM, Papp JC, Hämäläinen E, Broas P, Joslyn G, Hovatta I, Hiekkalinna T, Kaprio J, Ott J, Cantor RM, Zwart JA, Ilmavirta M, Havanka H, Färkkilä M, Peltonen L, Palotie A (2002) A susceptibility locus for migraine with aura on chromosome 4q24. *Am J Hum Genet* 70:652–662
71. Cader ZM, Noble-Topham S, Dyment DA, Cherny SS, Brown JD, Rice GP, Ebers GC (2003) Significant linkage to migraine with aura on chromosome 11q24. *Hum Mol Genet* 12:2511–2517
72. Russo L, Mariotti P, Sangiorgi E, Giordano T, Ricci I, Lupi F, Chiera R, Guzzetta F, Neri G, Gurrieri F (2005) A new susceptibility locus for migraine with aura in the 15q11–q13 genomic region containing three GABA-A receptor genes. *Am J Hum Genet* 76:327–333
73. Carlsson A, Forsgren L, Nylander PO, Hellman U, Forsman-Semb K, Holmgren G, Holmberg D, Holmberg M (2002) Identification of a susceptibility locus for migraine with and without aura on 6p12.2–p21.1. *Neurology* 59:1804–1807
74. Nyholt DR, Morley KI, Ferreira MA, Medland SE, Boomsma DI, Heath AC, Merikangas KR, Montgomery GW, Martin NG (2005) Genomewide significant linkage to migrainous headache on chromosome 5q21. *Am J Hum Genet* 77:500–512
75. Soragna D, Vettori A, Carraro G, Marchioni E, Vazza G, Bellini S, Tupler R, Savoldi F, Mostacciolo ML (2003) A locus for migraine without aura maps on chromosome 14q21.2–q22.3. *Am J Hum Genet* 72:161–167
76. Nyholt DR, Curtain RP, Griffiths LR (2000) Familial typical migraine: significant linkage and localization of a gene to Xq24–28. *Hum Genet* 107:18–23
77. McCarthy LC, Hosford DA, Riley JH, Bird MI, White NJ, Hewett DR, Peroutka SJ, Griffiths LR, Boyd PR, Lea RA, Bhatti SM, Hosking LK, Hood CM, Jones KW, Handley AR, Rallan R, Lewis KF, Yeo AJ, Williams PM, Priest RC, Khan P, Donnelly C, Lumsden SM, O'Sullivan J, See CG, Smart DH, Shaw-Hawkins S, Patel J, Langrish TC, Feniuk W, Knowles RG, Thomas M, Libri V, Montgomery DS, Manasco PK, Xu CF, Dykes C, Humphrey PP, Roses AD, Purvis IJ (2001) Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. *Genomics* 78:135–149
78. Curtain R, Tajouri L, Lea R, MacMillan J, Griffiths L (2006) No mutations detected in the INSR gene in a chromosome 19p13 linked migraine pedigree. *Eur J Med Genet* 49:57–62
79. Cupini LM, Massa R, Floris R, Manenti G, Martini B, Tessa A, Nappi G, Bernardi G, Santorelli FM (2003) Migraine-like disorder segregating with mtDNA 14484 Leber hereditary optic neuropathy mutation. *Neurology* 60:717–719
80. Ojaimi J, Katsabanis S, Bower S, Quigley A, Byrne E (1998) Mitochondrial DNA in stroke and migraine with aura. *Cerebrovasc Dis* 8:102–106
81. Majamaa K, Finnilä S, Turkka J, Hassinen IE (1998) Mitochondrial DNA haplogroup U as a risk factor for occipital stroke in migraine. *Lancet* 352:455–456
82. Boles RG, Williams JC (1999) Mitochondrial disease and cyclic vomiting syndrome. *Dig Dis Sci* 44:103S–107S
83. Boles RG, Adams K, Ito M, Li BU (2003) Maternal inheritance in cyclic vomiting syndrome with neuromuscular disease. *Am J Med Genet A* 120:474–482
84. Salpietro CD, Briuglia S, Merlino MV, Di Bella C, Rigoli L (2003) A mitochondrial DNA mutation (A3243G mtDNA) in a family with cyclic vomiting. *Eur J Pediatr* 162:727–728
85. Russell MB, Ostergaard S, Bendtsen L, Olesen J (1999) Familial occurrence of chronic tension-type headache. *Cephalalgia* 19:207–210
86. Cevoli S, Mochi M, Scapoli C, Marzocchi N, Pierangeli G, Pini LA, Cortelli P, Montagna P (2006) A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. *Eur J Neurol* 13:1009–1013
87. Mochi M, Cevoli S, Cortelli P, Pierangeli G, Scapoli C, Soriani S, Montagna P (2003) Investigation of an LDLR gene polymorphism (19p13.2) in susceptibility to migraine without aura. *J Neurol Sci* 213:7–10
88. Curtain R, Lea RA, Quinlan S, Bellis C, Tajouri L, Hughes R, Macmillan J, Griffiths LR (2004) Investigation of the low-density lipoprotein receptor gene and cholesterol as a risk factor for migraine. *J Neurol Sci* 227:95–100
89. D'Amico D, Moschiano F, Leone M, Ariano C, Ciusani E, Erba N, Grazzi L, Ferraris A, Schieroni F, Bussone G (1998) Genetic abnormalities of the protein C system: shared risk factors in

- young adults with migraine with aura and with ischemic stroke? *Cephalalgia* 18:618–621
90. Haan J, Kappelle LJ, de Ronde H, Ferrari MD, Bertina RM (1997) The factor V Leiden mutation (R506Q) is not a major risk factor for migrainous cerebral infarction. *Cephalalgia* 17:605–607
 91. Corral J, Iniesta JA, González-Conejero R, Lozano ML, Rivera J, Vicente V (1998) Migraine and prothrombotic genetic risk factors. *Cephalalgia* 18:257–260
 92. Soriani S, Borgna-Pignatti C, Trabetti E, Casartelli A, Montagna P, Pignatti PF (1998) Frequency of factor V Leiden in juvenile migraine with aura. *Headache* 38:779–781
 93. Haan J, Kappelle LJ, Ferrari MD, Bertina RM (1998) The transition G to A at position 20210 in the 3'-untranslated region of the prothrombin gene is not associated with migrainous infarction. *Cephalalgia* 18:229–230
 94. Iniesta JA, Corral J, González-Conejero R, Díaz Ortuño A, Martínez Navarro ML, Vicente V (2001) Role of factor XIII Val 34 Leu polymorphism in patients with migraine. *Cephalalgia* 21:837–841
 95. Paterna S, Di Pasquale P, D'Angelo A, Seidita G, Tuttolomondo A, Cardinale A, Maniscalchi T, Follone G, Giubilato A, Tarantello M, Licata G (2000) Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. *Eur Neurol* 43:133–136
 96. Griffiths LR, Nyholt DR, Curtain RP, Goadsby PJ, Brimage PJ (1997) Migraine association and linkage studies of an endothelial nitric oxide synthase (NOS3) gene polymorphism. *Neurology* 49:614–617
 97. Lea RA, Curtain RP, Shepherd AG, Brimage PJ, Griffiths LR (2001) No evidence for involvement of the human inducible nitric oxide synthase (iNOS) gene in susceptibility to typical migraine. *Am J Med Genet* 105:110–113
 98. Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alperovitch A (2001) Association between migraine and endothelin type A receptor (ETA-231 A/G) gene polymorphism. *Neurology* 56:1273–1277
 99. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K (2000) The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. *Am J Med Genet* 96:762–764
 100. Kara I, Sazci A, Ergul E, Kaya G, Kilic G (2003) Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. *Brain Res Mol Brain Res* 111:84–90
 101. Oterino A, Valle N, Pascual J, Bravo Y, Muñoz P, Castillo J, Ruiz-Alegría C, Sánchez-Velasco P, Leyva-Cobián F, Cid C (2005) Thymidylate synthase promoter tandem repeat and MTHFD1 R653Q polymorphisms modulate the risk for migraine conferred by the MTHFR T677 allele. *Brain Res Mol Brain Res* 139:163–168
 102. Ogilvie AD, Russell MB, Dhall P, Battersby S, Ulrich V, Smith CA, Goodwin GM, Harmar AJ, Olesen J (1998) Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. *Cephalalgia* 18:23–26
 103. Borroni B, Brambilla C, Liberini P, Rao R, Archetti S, Gipponi S, Volta GD, Padovani A (2005) Functional serotonin 5-HTTLPR polymorphism is a risk factor for migraine with aura. *J Headache Pain* 6:182–184
 104. Yilmaz M, Erdal ME, Herken H, Cataloluk O, Barlas O, Bayazit YA (2001) Significance of serotonin transporter gene polymorphism in migraine. *J Neurol Sci* 186:27–30
 105. Juhasz G, Zsombok T, Laszik A, Gonda X, Sotonyi P, Faludi G, Bagdy G (2003) Association analysis of 5-HTTLPR variants, 5-HT2a receptor gene 102T/C polymorphism and migraine. *J Neurogenet* 17:231–240
 106. Monari L, Mochi M, Valentino ML, Arnaldi C, Cortelli P, De Monte A, Pierangeli G, Prologo G, Scapoli C, Soriani S, Montagna P (1997) Searching for migraine genes: exclusion of 290 cM out of the whole human genome. *Ital J Neurol Sci* 18:277–282
 107. Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR (2000) Evidence for allelic association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical migraine. *Neurogenet* 3:35–40
 108. Erdal ME, Herken H, Yilmaz M, Bayazit YA (2001) Association of the T102C polymorphism of 5-HT2A receptor gene with aura in migraine. *J Neurol Sci* 188:99–101
 109. Nyholt DR, Curtain RP, Gaffney PT, Brimage P, Goadsby PJ, Griffiths LR (1996) Migraine association and linkage analyses of the human 5-hydroxytryptamine (5HT2A) receptor gene. *Cephalalgia* 16:463–467
 110. Buchwalder A, Welch SK, Peroutka SJ (1996) Exclusion of 5-HT2A and 5-HT2C receptor genes as candidate genes for migraine. *Headache* 36:254–258
 111. Johnson MP, Lea RA, Curtain RP, MacMillan JC, Griffiths LR (2003) An investigation of the 5-HT2C receptor gene as a migraine candidate gene. *Am J Med Genet B Neuropsychiatr Genet* 117:86–89
 112. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR (1998) Coronary side-effect potential of current and prospective antimigraine drugs. *Circulation* 98:25–30
 113. MaassenVanDenBrink A, Vergouve MN, Ophoff RA, Saxena PR, Ferrari MD, Frants RR (1998) 5-HT1B receptor polymorphism and clinical response to sumatriptan. *Headache* 38:288–291
 114. Peroutka SJ, Price SC, Wilhoit TL, Jones KW (1998) Comorbid migraine with aura, anxiety, and depression is associated with dopamine D2 receptor (DRD2) NcoI alleles. *Mol Med* 4:14–21
 115. Del Zompo M, Cherchi A, Palmas MA, Ponti M, Bocchetta A, Gessa GL, Piccardi MP (1998) Association between dopamine receptor genes and migraine without aura in a Sardinian sample. *Neurology* 51:781–786
 116. Dichgans M, Förderreuther S, Deiterich M, Pfaffenrath V, Gasser T (1998) The D2 receptor NcoI allele: absence of allelic association with migraine with aura. *Neurology* 51(3):928
 117. Montagna P, Cevoli S, Marzocchi N, Pierangeli G, Pini LA, Cortelli P, Mochi M (2003) The genetics of chronic headaches. *Neurol Sci* 24:S51–S56
 118. Maude S, Curtin J, Breen G, Collier D, Russell G, Shaw D, Clair DS (2001) The -141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease. *Psychiatr Genet* 11:49–52
 119. Rebaudengo N, Rainero I, Parziale A, Rosina F, Pavanelli E, Rubino E, Mazza C, Ostacoli L, Furlan PM (2004) Lack of interaction between a polymorphism in the dopamine D2 receptor gene and the clinical features of migraine. *Cephalalgia* 24:503–507
 120. Shepherd AG, Lea RA, Hutchins C, Jordan KL, Brimage PJ, Griffiths LR (2002) Dopamine receptor genes and migraine with and without aura: an association study. *Headache* 42:346–351
 121. Marziniak M, Mössner R, Benninghoff J, Syagailo YV, Lesch KP, Sommer C (2004) Association analysis of the functional monoamine oxidase A gene promoter polymorphism in migraine. *J Neural Transm* 111:603–609
 122. Fernandez F, Lea RA, Colson NJ, Bellis C, Quinlan S, Griffiths LR (2006) Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. *J Neurol Sci* 251:118–123

123. Mochi M, Cevoli S, Cortelli P, Pierangeli G, Soriani S, Scapoli C, Montagna P (2003) A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-beta-hydroxylase genes. *Neurol Sci* 23:301–305
124. Colson NJ, Lea RA, Quinlan S, MacMillan J, Griffiths LR (2005) Investigation of hormone receptor genes in migraine. *Neurogenetics* 6:17–23
125. Mössner R, Weichselbaum A, Marziniak M, Freitag CM, Lesch KP, Sommer C, Meyer J (2005) A highly polymorphic polyglutamine stretch in the potassium channel KCNN3 in migraine. *Headache* 45:132–136
126. Curtain R, Sundholm J, Lea R, Ovcacic M, MacMillan J, Griffiths L (2005) Association analysis of a highly polymorphic CAG Repeat in the human potassium channel gene KCNN3 and migraine susceptibility. *BMC Med Genet* 14:32–39
127. Lulli P, Trabace S, Morellini M, Ciciarelli G, Coloprisco G, Piane M, de Filippis S, Santi PG, Avramakou O, Ferlicca E, Martelletti P (2005) Cytotoxic T lymphocyte antigen 4 polymorphism 49 (A > G) and migraine. *J Headache Pain* 6:188–190
128. Rainero I, Fasano E, Rubino E, Rivoiro C, Valfrè W, Gallone S, Savi L, Gentile S, Lo Giudice R, De Martino P, Dall’Omo AM, Pinessi L (2005) Association between migraine and HLA-DRB1 gene polymorphisms. *J Headache Pain* 6:185–187
129. Couturier EG, Hering R, Steiner TJ (1991) The first report of cluster headache in identical twins. *Neurology* 41:761
130. Roberge C, Bouchard JP, Simard D, Gagné R (1992) Cluster headache in twins. *Neurology* 42:1255–1256
131. Schuh-Hofer S, Meisel A, Reuter U, Arnold G (2003) Monozygotic twin sisters suffering from cluster headache and migraine without aura. *Neurology* 60:1864–1865
132. Sjaastad O, Shen JM, Stovner LJ, Elsås T (1993) Cluster headache in identical twins. *Headache* 33:214–217
133. Spierings EL, Vincent AJ (1992) Familial cluster headache: occurrence in three generations. *Neurology* 42:1399–1400
134. Alberca R, Aguilera JM, Casado JL, López JM, Arenas C, Moreno A, Serrano V (1994) Cluster headache with a familial presentation. *Neurologia* 9:22–24
135. Bordini CA, Arruda MA, Ciciarelli M, Daripa M, Martins Coelho J, Speciali JG (1997) Cluster headache: report of seven cases in three families. *Funct Neurol* 12:277–282
136. D’Amico D, Leone M, Moschiano F, Bussone G (1996) Familial cluster headache: report of three families. *Headache* 36:41–43
137. De Simone R, Fiorillo C, Bonuso S, Castaldo G (2003) A cluster headache family with possible autosomal recessive inheritance. *Neurology* 61:578–579
138. Russell MB, Andersson PG, Thomsen LL (1995) Familial occurrence of cluster headache. *J Neurol Neurosurg Psychiatry* 58:341–343
139. Russell MB, Andersson PG, Thomsen LL, Iselius L (1995) Cluster headache is an autosomal dominantly inherited disorder in some families: a complex segregation analysis. *J Med Genet* 32:954–956
140. Russell MB, Andersson PG, Iselius L (1996) Cluster headache is an inherited disorder in some families. *Headache* 36:608–612
141. Montagna P, Mochi M, Prologo G, Sangiorgi S, Pierangeli G, Cavoli S, Cortelli P (1998) Heritability of cluster headache. *Eur J Neurol* 5:343–345
142. Russell MB (2004) Epidemiology and genetics of cluster headache. *Lancet Neurol* 3:279–283
143. El Amrani M, Ducros A, Boulan P, Aidi S, Crassard I, Visy JM, Tournier-Lasserve E, Bousser MG (2002) Familial cluster headache: a series of 186 index patients. *Headache* 42:974–977
144. Svensson D, Ekbom K, Pedersen NL, Träff H, Waldenlind E (2003) A note on cluster headache in a population-based twin register. *Cephalalgia* 23:376–380
145. Shimomura T, Kitano A, Marukawa H, Mishima K, Isoe K, Adachi Y, Takahashi K (1994) Point mutation in platelet mitochondrial tRNA (Leu(UUR)) in patient with cluster headache. *Lancet* 344:625
146. Cortelli P, Zacchini A, Barboni P, Malpassi P, Carelli V, Montagna P (1995) Lack of association between mitochondrial tRNA(Leu(UUR)) point mutation and cluster headache. *Lancet* 345:1120–1121
147. Seibel P, Grünwald T, Gundolla A, Diener HC, Reichmann H (1996) Investigation on the mitochondrial transfer RNA(-Leu)(UUR) in blood cells from patients with cluster headache. *J Neurol* 243:305–307
148. Odawara M, Tamaoka A, Mizusawa H, Yamashita K (1997) A case of cluster headache associated with mitochondrial DNA deletions. *Muscle Nerve* 20:394–395
149. Cuypers J, Altenkirch H (1979) HLA antigens in cluster headache. *Headache* 19:228–229
150. Martelletti P, Romiti A, Gallo MF, Giacobuzzo M, Adorno D, Valeri M, Piazza A, Monaco PI, Casciani CU (1984) HLA-B14 antigen in cluster headache. *Headache* 24:152–154
151. Giacobuzzo M, Martelletti P, Romiti A, Gallo MF, Iuvara E, Valeri M, Piazza A, Adorno D, Monaco PI, Casciani CU (1986) Genetic markers of cluster headache and the links with the lithium salts therapy. *Int J Clin Pharmacol Res* 6:19–22
152. Sjöstrand C, Giedratz V, Ekbom K, Waldenlind E, Hillert J (2001) CACNA1A gene polymorphisms in cluster headache. *Cephalalgia* 21:953–958
153. Haan J, van Vliet JA, Kors EE, Terwindt GM, Vermeulen FL, van den Maagdenberg AM, Frants RR, Ferrari MD (2001) No involvement of the calcium channel gene (CACNA1A) in a family with cluster headache. *Cephalalgia* 21:959–962
154. Sjöstrand C, Modin H, Masterman T, Ekbom K, Waldenlind E, Hillert J (2002) Analysis of nitric oxide synthase genes in cluster headache. *Cephalalgia* 22:758–764
155. Aridon P, D’Andrea G, Rigamonti A, Leone M, Casari G, Bussone G (2004) Elusive amines and cluster headache: mutational analysis of trace amine receptor cluster on chromosome 6q23. *Neurol Sci* 25(Suppl 3):S279–S280
156. Cevoli S, Mochi M, Pierangeli G, Zanigni S, Grimaldi D, Bonavina G, Torelli P, Manzoni GC, Cortelli P, Montagna P (2008) Investigation of the T3111C CLOCK gene polymorphism in cluster headache. *J Neurol* Feb 20 [Epub ahead of print]
157. Rainero I, Rivoiro C, Gallone S, Valfrè W, Ferrero M, Angilella G, Rubino E, De Martino P, Savi L, Lo Giudice R, Pinessi L (2005) Lack of association between the 3092 T→C Clock gene polymorphism and cluster headache. *Cephalalgia* 25:1078–1081
158. Rainero I, Rivoiro C, Rubino E, Milli V, Valfrè W, De Martino P, Lo Giudice R, Angilella G, Savi L, Gallone S, Pinessi L (2005) Prevalence of HFE (hemochromatosis) gene mutations in patients with cluster headache. *Headache* 45:1219–1223
159. Rainero I, Gallone S, Valfrè W, Ferrero M, Angilella G, Rivoiro C, Rubino E, De Martino P, Savi L, Ferrone M, Pinessi L (2004) A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. *Neurology* 63:1286–1288
160. Schürks M, Kurth T, Geissler I, Tzschaschke G, Diener HC, Roskopf D (2006) Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene. *Neurology* 66:1917–1919
161. Baumber L, Sjöstrand C, Leone M, Harty H, Bussone G, Hillert J, Trembath RC, Russell MB (2006) A genome-wide scan and HCTR2 candidate gene analysis in a European cluster headache cohort. *Neurology* 66:1888–1893
162. Siow HC, Young WB, Peres MF, Rozen TD, Silberstein SD (2002) Hemiplegic cluster. *Headache* 42:136–139

163. Sjöstrand C, Duvefelt K, Steinberg A, Remahl IN, Waldenlind E, Hillert J (2006) Gene expression profiling in cluster headache: a pilot microarray study. *Headache* 46:1518–1534
164. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suñer D, Cigudosa JC, Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M (2005) Epigenetic differences arise during the lifetime of monozygotic twins. *Proc Natl Acad Sci USA* 102:10604–10609
165. Oommen AM, Griffin JB, Sarath G, Zempleni J (2005) Roles for nutrients in epigenetic events. *J Nutr Biochem* 16:74–77
166. Champagne FA, Francis DD, Mar A, Meaney MJ (2003) Variations in maternal care in the rat as a mediating influence for the effects of environment on development. *Physiol Behav* 79:359–371
167. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ (2004) Epigenetic programming by maternal behavior. *Nat Neurosci* 7:847–854
168. Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, Szyf M (2005) Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. *J Neurosci* 25:11045–11054
169. Karten YJ, Olariu A, Cameron HA (2005) Stress in early life inhibits neurogenesis in adulthood. *Trends Neurosci* 28:171–172
170. Vicentic A, Francis D, Moffett M, Lakatos A, Rogge G, Hubert GW, Harley J, Kuhar MJ (2006) Maternal separation alters serotonergic transporter densities and serotonergic 1A receptors in rat brain. *Neuroscience* 140:355–365
171. Burlet G, Fernet B, Blanchard S, Angel E, Tankosic P, Mac-cari S, Burlet A (2005) Antenatal glucocorticoids blunt the functioning of the hypothalamic–pituitary–adrenal axis of neonates and disturb some behaviors in juveniles. *Neuroscience* 133:221–230
172. Yoshihara T, Otsuki Y, Yamazaki A, Honma S, Yamasaki Y, Honma K (2005) Maternal deprivation in neonatal rats alters the expression of circadian system under light–dark cycles and restricted daily feeding in adulthood. *Physiol Behav* 85:646–654
173. Levenson JM, Sweatt JD (2005) Epigenetic mechanisms in memory formation. *Nat Rev Neurosci* 6:108–118
174. Hong EJ, West AE, Greenberg ME (2005) Transcriptional control of cognitive development. *Curr Opin Neurobiol* 15:21–28
175. Petronis A (2004) The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. *Biol Psychiatry* 55:965–970
176. Gottesman II, Hanson DR (2005) Human development: biological and genetic processes. *Annu Rev Psychol* 56:263–286
177. Bjornsson HT, Fallin MD, Feinberg AP (2004) An integrated epigenetic and genetic approach to common human disease. *Trends Genet* 20:350–358
178. Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease susceptibility. *Nat Rev Genet* 8:253–262
179. Vercelli D (2004) Genetics, epigenetics, and the environment: switching, buffering, releasing. *J Allergy Clin Immunol* 113:381–386
180. Savi L, Buccheri R, Tambornini A, De Martino P, Albasi C, Pinessi L (2005) Attachment styles and headache. *J Headache Pain* 6:254–257
181. Rossi P, Di Lorenzo G, Malpezzi MG, Di Lorenzo C, Cesarino F, Faroni J, Siracusano A, Troisi A (2005) Depressive symptoms and insecure attachment as predictors of disability in a clinical population of patients with episodic and chronic migraine. *Headache* 45:561–570
182. Ventegodt S, Flensburg-Madsen T, Andersen NJ, Merrick J (2005) Events in pregnancy, delivery, and infancy and long-term effects on global quality of life: results from the Copenhagen Perinatal Birth Cohort 1959–61. *Med Sci Monit* 11:CR357–CR365
183. Blau JN (1992) Migraine: theories of pathogenesis. *Lancet* 339:1202–1209
184. Welch KM (1986) Migraine: a biobehavioural disorder. *Cephalalgia* 6:103–110
185. Montagna P, Cortelli P (2008) Migraine and the autonomic nervous system. In: Low PA (ed) *Clinical autonomic disorders: evaluation and management*. Lippincott, Williams and Wilkins, Philadelphia (in press)
186. Hart BL (1988) Biological basis of the behavior of sick animals. *Neurosci Biobehav Rev* 12:123–137
187. Blau JN (1993) Behaviour during a cluster headache. *Lancet* 342:723–725
188. Loder E (2002) What is the evolutionary advantage of migraine? *Cephalalgia* 22:624–32